Shenzhen YHLO Biotech Co., Ltd. (688575.SS) SHH
10.34
-0.17(-1.62%)
Currency In CNY
- General
- Statistics
- Historical Data
- Profile
- Financials
10.34
-0.17(-1.62%)
Currency In CNY
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Employees
1759
First IPO Date
May 17, 2021
| Name | Title | Pay | Year Born |
| Mingyang Wang | Secretary of the Board | 0 | 1989 |
| Yongbo Song | GM & Vice Chairman of the Board | 0 | 1984 |
| Chun Gen Qian | Deputy GM & Director | 0 | 1982 |
| Lisheng Liao | Chief Financial Officer & Director | 0 | 1979 |
| Yujing Xiao | Deputy General Manager | 0 | 1976 |
Shenzhen YHLO Biotech Co., Ltd. engages in developing, manufacturing, and distributing in-vitro diagnostic instruments and reagents in China. It offers clinical solutions for autoimmune, reproductive health, infectious, and other diseases; CLIA test panels, chemiluminescence immunoassay analyzers, and integration systems for immunoassay; ELISA test panels and immune analyzers; LIA test panels, blot analyzers, and line immunoassays; POCT test panels and immunofluorescence readers; ESR Analyzers; and COVID-19 detection kits. The company also exports its COVID-19 detection kits to various countries, including Germany, France, Italy, Denmark, Sweden, etc. Shenzhen YHLO Biotech Co., Ltd. was founded in 2008 and is headquartered in Shenzhen, China.